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The Third International Workshop for Glycosylation Defects in
Muscular Dystrophies took place on 18–19 April 2013. It was held
at the Omni Charlotte in Charlotte, NC, USA and hosted by the
McColl-Lockwood Laboratory for Muscular Dystrophy Research,
the Carolinas Medical Center and the Carolinas Education
Institute. The event was sponsored by the Carolinas Healthcare
Foundation, the Muscular Dystrophy Association (MDA), funds
raised by “Jeans, Genes and Geniuses” organized by Jane and
Luther Lockwood, as well as generous support by the McColl and
Lockwood families. Since its founding in 2008, the International
Workshop for Glycosylation Defects in Muscular Dystrophies has
been a platform for bringing together top scientists and clinicians
from around the world to discuss current research in the area of
dystroglycanopathies [forms of muscular dystrophy associated
with the hypoglycosylation of alpha-dystroglycan (α-DG) ] as well
as providing a setting to facilitate collaborations. For this work-
shop, 22 scientists and clinicians were brought in from the US, UK
and Japan for a total of 23 talks spread over 2 days. Over the past
2 years, significant progress has been made in the dystroglyca-
nopathy field. Such advances include a greater knowledge of the
mechanisms involved in the glycosylation of α-DG, the identifi-
cation of additional genes that, when carrying mutations, are
involved in the disease process and the development of new animal
models and their use in developing new targets for treatment. New
data have become available for adeno-associated virus (AAV)-
mediated gene therapy in FKRP (fukutin-related protein) deficient
animal models and compound library screening has taken place
in several labs resulting in multiple hits with the potential for
upregulating the functional glycosylation of α-DG and other pro-
teins. As a testament to the progress being made, this year’s work-
shop devoted an entire session to discussing clinical treatments,
management and endpoints. The 2013 workshop focused on the
following topics: mechanisms involved in α-DG glycosylation and
newly developed animal models for examining pathways and
disease targets; AAV therapy and drug discovery, including pos-
sible mechanisms and targets for treating dystroglycanopathies;
genetic diagnosis, clinical management and endpoint markers,
including current data from clinical trials and methods for assess-
ing treatments. The audience included members of Carolinas
Medical Center, Children’s National Medical Center D.C.,
Genzyme Corporation, BioMarin Pharmaceuticals, Pfizer Corpo-
ration and University of Massachusetts Medical School.
BACKGROUND
Dystroglycan is a key component of the dystrophin glycoprotein
complex (DGC). It is encoded by a single gene (Dag1), the tran-
script of which is post-translationally cleaved into two subunits,
alpha and beta.α-DG is heavily glycosylated and the sugar moieties
in the central mucin-like region play an essential role in the binding
to various extracellular matrix components such as laminin,
perlecan and agrin. Alterations in the glycosylation of α-DG result
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in a subset of muscular dystrophies referred to as dystroglycano-
pathies (14). The diseases vary in severity from the severe Walker–
Warburg syndrome (WWS) and muscle–eye–brain (MEB) disease,
which display structural brain involvement in addition to muscular
dystrophy, to the relatively mild forms of limb–girdle muscular
dystrophy (LGMD) such as LGMD2I with little or no central
nervous system (CNS) involvement (5, 13). The dystroglycano-
pathies have so far been associated with mutations in up to 16
putative or demonstrated glycosyltransferases, which include
LARGE, fukutin, FKRP, POMT1, POMT2 and POMGnT1, each of
which result in the aberrant glycosylation ofα-DG (2, 4, 11, 12, 23).
However, there are still a large proportion of patients with reduced
α-DG glycosylation that lack a defined genetic diagnosis. At the
current time, there is no effective therapy available for dystrogly-
canopathies. A number of animal models have been described
previously, but no experimental therapy has been reported. The
pathway leading to the functional glycosylation of α-DG is not
clearly understood, and reagents and methods for identifying diver-
sity of glycosylated α-DG remain a challenge. Research in all these
areas has made significant progress during the last 2 years as
presented during the meeting. At the same time, clinic preparation
has geared up for future clinic trials with several lines of experi-
mental therapies emerging from the ongoing translational research.
REPORT SUMMARY
Glycosylation
The workshop began with opening remarks by Bernard Brigonnet,
Vice President of Research, Carolinas Healthcare System. The
first session was chaired by James Ervasti from the University of
Minnesota Department of Biochemistry, Molecular Biology and
Biophysics.
To start the session Dr. James Ervasti shared his view of the
more complex nature of α-DG glycosylation in muscle and the
difficulties associated with determining the status of so-called
functional glycosylation, a critical step if we are to understand the
function of each of the so-called “glycosylation” genes in the
glycosylation process. Sample preparation, sample buffer compo-
sition and pH, denaturation temperature and duration, as well as
protease inhibiters could all affect the size and signal intensity of
the species of α-DG glycosylation detected by IIH6 (an antibody
commonly used to identify the glycosylation status of α-DG) and
laminin-binding assays. Dr. Ervasti suggested that greater care
should be taken to standardize blotting procedures for detecting
α-DG and data interpretation. This also raised the need to develop
new reagents for possibly more reliable determination of α-DG
glycosylation status (see below). Work from Dr. Ervasti’s lab also
suggested a possible interaction between dystroglycan and other
membrane-associated proteins such as caveolin, which might play
a role for maintaining muscle fiber stability (10).
To address the difficulty in detecting dystroglycan reliably, Dr.
Glenn Morris presented his lab’s efforts (with support from
LGMD2I Fund) to generate specific monoclonal antibodies for
functionally glycosylated α- and β-DG. Dr. Morris reported initial
evidence that clones of such antibodies have been created.
However, further selection and characterization are required.
Using a zebra fish model system, Dr. Tamao Endo illustrated his
studies showing that POMT1/2 play an essential role in the normal
development of zebra fish through the O-mannosylation of α-DG.
Whilst the glycosylation of α-DG is important for maintaining
muscle stability, the regulation of this process remains largely
unknown. Dr. Endo reported the importance of human natural
killer-1 sulfotransferase (HNK-1ST) in modulating function of
α-DG. Using a coexpression system in retinoic acid-treated S91
melanoma cells, Dr. Endo showed that expression of HNK-1ST
mediated the incorporation of sulfate into α-DG. This is associated
with suppressed expression and reduced ligand-binding activity of
α-DG in the presence and absence of LARGE overexpression. The
results suggest that sulfotransferase activity of HNK-1ST may be
one of the mechanisms modulating α-DG glycosylation though the
precise pathways are not understood.
Dr. Susan Brown has followed up her earlier study of developing
an FKRP knockdownneoY307N mutant mouse model. The original
model proved to be embryonic and perinatal lethal. By crossbreed-
ing with a strain of mouse expressing Cre recombinase under the
SOX-1 promoter, Dr. Brown reported the creation of a new line
with the restoration of functional α-DG glycosylation in the CNS
but not skeletal muscle, thus producing viable mice with clear
dystrophic phenotype. This model will now be more useful for
mechanistic and therapeutic studies.
Dr. Anthony Blaeser presented further data in FKRP mouse
model characterization conducted in McColl-Lockwood Lab.
Through crossbreeding of original strains of FKRP mutants with
P448L, L276I and E310X nonsense mutation, a set of mouse
models with wide range of disease severity has been created with
dystrophic phenotypes ranging from very mild, limb–girdle mus-
cular dystrophy 2I, to severe Walker–Warburg syndrome and
muscle–eye–brain disease with brain and eye defects (3, 8). These
animal models will play a crucial role in understanding the mecha-
nisms of α-DG glycosylation as well as in developing experimental
therapies.
Dystroglycan phosphorylation was suggested as a new thera-
peutic target for dystroglycanopathies by Dr. Steve Winder. Dr.
Winder proposed that the tyrosine phosphorylation of β-DG plays
a crucial role in the loss of DGC from the membrane and might
represent a therapeutic target. Using mouse myoblasts, Dr. Winder
was able to demonstrate an increase in non-phosphorylated
dystroglycan. Also, in sapje (dystrophin-deficient) zebra fish, the
inhibition of tyrosine phosphorylation was able to rescue the dys-
trophic phenotype.
Dr. Huaiyu Hu presented new data suggesting a role for
glycosyltranferases in neural development. Using POMGnT1
knockout mice, Dr. Hu demonstrated that the hypoglycosylation of
α-DG resulted in the disruption of basement membrane assembly
during neural tissue development, leading to reduced levels of key
basement membrane components and the weakening of the base-
ment membrane. This could be the mechanism involved in the
alteration of neuronal migration.
To explore regulatory pathways of α-DG glycosylation, Dr.
Minoru Fukuda applied the siRNA library screening technique and
identified Fer kinase as a key regulator of laminin-binding glycan
expression on breast and prostate cancer cells (22). Dr. Fukuda
demonstrated that knockdown of Fer kinase increased transcrip-
tion levels of β3GnT1 and LARGE. However, expression of Fert2,
(a homolog of Fer) in mouse C2C12 myoblast cells, downregulated
β3GntT1 expression but not LARGE. The knockdown of Fert2
was able to upregulate laminin-binding glycan expression and
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myotube formation, suggesting a novel role of Fer kinase in
glycosylation regulation.
Dr. Kevin Campbell presented data of LARGE function in the
glycosylation of α-DG. Dr. Campbell demonstrated the bifunc-
tionality of LARGE with both xylosyltransferase and glucoronyl-
transferase activities (9). These activities play an important role in
the laminin-binding efficiency of glycosylated α-DG.
AAV THERAPY/DRUG DISCOVERY
The second session was chaired by Qi Long Lu from the Carolinas
Medical Center. Dr. Xiao Xiao began the session by discussing the
use of AAV9 vectors for the delivery of FKRP to L276I-FKRP
mutant mice, which exhibit a mild disease phenotype with late
onset. It was apparent that the expression of a human FKRP
transgene restored glycosylation of α-DG and ameliorated the
dystrophic pathology in both skeletal and cardiac muscles. Dr. Qi
Long Lu further demonstrated the effectiveness of AAV9-FKRP
therapy in FKRP-P448Lneo mutant mice, which present moderate
dystrophic phenotype with disease onset before 4 weeks of age.
Dr. Lu showed that AAV-FKRP treatment was able to restore the
functional glycosylation of α-DG in all skeletal and heart muscles.
This led to a significant improvement in muscle pathology,
strength and serum markers. No detectable toxicity was observed,
suggesting the feasibility of gene therapy as an effective treatment
for FKRP-related muscular dystrophies.
In line with the effort to move FKRP gene therapy using AAV
vectors toward clinic trials, Dr. John Gray introduced clinical trials
using AAV8-mediated gene therapy in Hemophilia B patients.
Preliminary results from this study proved to be encouraging with
patients maintaining expression at 1%–6% normal levels after a
period of 1.5 years. However, cell-mediated immunity to AAV8
remains a concern with some of the high-dose cohort patients
showing elevated levels of AAV8 capsid-specific T-cells.
Dr. Tatsushi Toda discussed the use of antisense oligonucleo-
tides targeting various splice acceptor and enhancer sites to
prevent pathogenic exon-trapping in Fukuyama congenital muscu-
lar dystrophy (FCMD) mouse models and the cells of patients with
FCMD. The disease is largely the result of retrotransposal insertion
in the 3′ UTR region of the fukutin gene, leading to the altered
splicing and the addition of a new sequence in the 3′ end of the
transcript with loss of function. Dr. Toda designed specific anti-
sense oligonucleotides targeting splicing acceptor and enhancer
sites for restoration of normal fukutin protein and reported success
in doing so by using a cocktail of antisense oligonucleotides in
both human cells and in the mouse model. Dr. Toda also presented
data supporting the hypothesis that FKRP is also involved in the
post-phosphoryl modification of α-DG. In addition, Dr. Toda
reported two distinct fukutin conditional knockout (cKO) mice
and AAV9-fukutin therapy. They proposed that myofiber-selective
expression of fukutin can also be an effective therapeutic strategy.
Using cell-based assays on patient-derived cells, Dr. Anne Bang
has developed a 384-well based assay for identifying lead com-
pounds to treat LGMD2I. A screening of 6000 pharmacologically
active compounds resulted in the identification of nine compounds
that increase laminin binding in FKRP-deficient patient cells. Dr.
Bang has also developed induced pluripotent stem cells (iPSC)
from dystroglycanopathy patient-derived tissue. This will allow
Dr. Bang to further differentiate the iPSC into disease-relevant cell
types including myogenic cells and myofibers, cardiomyocytes,
and neural cells. This could be highly valuable for drug screening
as effect of any potential compound may well be cell-specific.
Dr. Xiaohua Wu reported his finding on drug screening of a
larger library with about 420 000 small compounds in Chinese
hamster ovary (CHO) cells with glycosylation levels and lami-
nin binding as a readout. Several dozen compounds were iden-
tified that significantly increase the expression of functionally
glycosylated α-DG. However, the enhanced expression of α-DG
appears to be cell-type dependant, suggesting cell-specific regula-
tory mechanisms may underlie functional glycosylation. Dr. Wu
emphasized the importance of cell-type specificity of drug
response and the need to establish more relevant in vitro screen
system for further drug development. Another strategy for drug
screening was adopted by Dr. Lou Kunkel. Dr. Kunkel screened a
drug library in dystroglycan-null zebra fish, in an attempt to find
candidate compounds capable of alleviating the dystrophic pheno-
type. Preliminary screening resulted in 11 candidates that prevent
muscle pathology in short-term treatments. Of these compounds,
one was able to dramatically increase the survival of dystroglycan-
null zebra fish and reverse the pathology. This is interesting as it
implies that factors other than functional glycosylated α-DG are
able to compensate for the lack of dystroglycan. Dr. Kunkel is
further testing the candidate drug in different cell and animal
model systems.
Currently, immunohistochemistry and western blot are the
most widely used methods of detecting functionally glycosylated
α-DG. However, Dr. Francesco Muntoni demonstrated the use
of flow cytometry for the detection of IIH6-reactive functionally
glycosylated α-DG in patients-derived fibroblasts. The results
show that the levels of glycosylated α-DG in fibroblasts are com-
parable to that in patient-derived skeletal muscle cells, supporting
the view that examination of fibroblasts in conjunction with flow
cytometry could be of diagnostic value for dystroglycanopathies.
Dr. Muntoni also applied flow cytometry for drug screening with a
library of about 1000 compounds and reported several hits with
increase in α-DG glycosylation. Dr. Muntoni suggested the use of
flow cytometry as a platform for conducting high throughput
assays.
CLINICAL MANAGEMENT/ENDPOINTS
The final session was chaired by Susan Sparks from the Carolinas
Medical Center. Dr. Francesco Muntoni returned to discuss the
identification of a number of novel genes, mutations in which are
associated with a dystroglycanopathy phenotype. These included at
least six other genes in the last 2 years and include:—B3GALnT2, a
glycosyltransferase located in the endoplasmic reticulum, muta-
tions in which were found to underlie WWS and MEB (18);
GDP-mannose pyrophosphorylase B (GMPPB), mutations in
which were identified in patients with varying severities of disease
from MEB to LGMD (7); isoprenoid synthase domain containing
(ISPD) gene, mutations in which were shown in individuals with
severe WWS (16, 20) and subsequently milder LGMD (19); doli-
chol synthesis (DPM1 and DPM2), mutations in which were
associated with a dystroglycanopathy-type congenital muscular
dystrophy (1, 21); B3GNT1, mutations in which were found to
underlie WWS (6, 17); GTDC2, mutations in which were identified
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in patients with WWS (15); and finally SGK196, mutations in which
were associated with congenital muscular dystrophy (24).
Dr. Susan Sparks reported on a study of expression profiling in
patients by looking at the expression of various growth factors and
cytokines in LGMD patients with FKRP mutations. Dr. Sparks
identified 373 transcripts, which are differentially expressed com-
pared with normal controls. The results showed that FKRP patients
contain more downregulated transcripts than typically seen in
other dystrophies. Of note was the downregulation of genes
involved in the TGF-B and IGF-II signaling pathways, which are
generally upregulated in other dystrophies. Identifying biomarkers
specific for FKRP-dystroglycanopathies and disease progression
remains to be investigated, but crucial for clinic evaluation of any
experimental therapy.
Dr. Madhuri Hegde addressed the issue of identifying disease
subtypes through the use of next-generation sequencing and whole
exomes. She reviewed the current technology, utilization and limi-
tations. Utilizing patient-derived data, including sequencing and
phenotypes, known and unknown variants can be catalogued using
a newly established website. This site can then be used to examine
relevant genes associated with a patient’s clinical presentation.
This allows enhanced evaluation for clinical phenotypes.
Tina Duong continued the discussion of evaluating clinical
outcome measures in patients with LGMD. Examining various
conditions, based on strength and functional tests, baseline meas-
ures were established for a variety of LGMD subtypes. When
compared with other LGMD subtypes, patients with FKRP
showed lower forced vital capacity and sparing of grip strength.
Additionally, 6-minute walking test (MWT) values seem to be
more highly correlated to lower extremity strength than respiratory
function. Results from this pilot study validate previously pub-
lished works on FKRP phenotype using a much smaller cohort and
would help in future experimental designs and outcomes selection.
Dr. Volker Straub assessed LGMD patients with FKRP of differ-
ent clinical severities with similar evaluation methods as those
described by Tina Duong. He also included muscle magnetic reso-
nance imaging (MRI) and magnetic resonance spectroscopy (MRS)
showing a correlation between fat infiltration and muscle function.
Dr. Straub suggests that quantitative MRI is better suited to mea-
sure disease progression than physical assessments. Furthermore,
Dr. Straub presented the global FKRP registry websites (https://
www.fkrp-registry.org) to identify potential patients eligible for
clinical trials as well as providing a better understanding of the
prevalence and distribution of those affected by FKRP mutations.
The final talk of the session was given by Dr. Claudia Mitchell
regarding various research supported by the LGMD2I Research
Fund. These include research in developing patient iPS cells, anti-
bodies to α-DG, various FKRP animal models and drug screening
as well as various experimental therapies. The Fund is also
involved in the formation of various websites and clinical trials as
well as discussing social media avenues to encourage patient
involvement in research.
WORKSHOP ORGANIZERS
The workshop was organized with the help of Dr. Qi Long Lu, Dr.
Anthony Blaeser, Dr. Kevin Campbell, Dr. Susan Sparks, Jeannie
Maggio, Cameron Davis, Caren Anderson and Ashley Katkin.
LIST OF SPEAKERS
(i) Anne Bang, Sanford-Burnham Medical Research Institute
(ii) Anthony Blaeser, Carolinas Medical Center
(iii) Susan Brown, Royal Veterinary College, University of
London
(iv) Kevin Campbell, University of Iowa
(v) Tina Duong, Children’s National Medical Center
(vi) Tamao Endo, Tokyo Metropolitan Institute of Gerontology
(vii) James Ervasti, University of Minnesota
(viii) Minoru Fukuda, Sanford-Burnham Medical Research
Institute
(ix) John Gray, St. Jude Children’s Research Hospital
(x) Madhuri Hegde, Emory University School of Medicine
(xi) Huaiyu Hu, SUNY Upstate Medical University
(xii) Louis Kunkel, Boston Children’s Hospital
(xiii) Qi Long Lu, Carolinas Medical Center
(xiv) Claudia Mitchell, LGMD2i Research Fund
(xv) Glenn Morris, Robert Jones & Agnes Hunt Orthopaedic
Hospital
(xvi) Francesco Muntoni, University College London
(xvii) Susan Sparks, Levine Children’s Hospital
(xviii) Volker Straub, Newcastle University
(xix) Tatsushi Toda, Kobe University
(xx) Steve Winder, University of Sheffield
(xxi) Xiaohua Wu, Carolinas Medical Center
(xxii) Xiao Xiao, University of North Carolina at Chapel Hill
WORKSHOP WEBSITE
A website for the Third International Workshop for Glycosylation
Defects can be accessed at http://www.carolinashealthcare.org/
md-international-workshop.
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